Stock RACA THES ACQU
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

THES ACQU

Equities

RACA

US88339T1034

Biotechnology & Medical Research

LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about THES ACQU

Therapeutics Acquisition Corp.(NasdaqCM:RACA) dropped from NASDAQ Composite Index CI
Point Biopharma Inc. completed the acquisition of Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction. CI
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC CI
Therapeutics Acquisition : Point Biopharma Phase 3 Trial for Cancer Therapy Doses First Patient Group MT
Therapeutics Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Merck : Completes Pandion Therapeutics Acquisition MT
Therapeutics Acquisition : POINT Biopharma To Go Public Via SPAC Combination MT
Point Biopharma Inc. entered into a non-binding letter of intent to acquire Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction. CI
Therapeutics Acquisition Corp.(NasdaqCM:RACA) added to NASDAQ Composite Index CI
Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million. CI
Certain Class B Common Stock of Therapeutics Acquisition Corp. are subject to a Lock-Up Agreement Ending on 5-JAN-2021. CI
Therapeutics Acquisition Corp. has filed an IPO in the amount of $100 million. CI

Chart THES ACQU

Chart THES ACQU
More charts

Company Profile

POINT Biopharma Inc., formerly Therapeutics Acquisition Corp, is a late-stage clinical precision oncology company. The Company focuses on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's product candidates include PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. PNT2003 combines a somatostatin-specific radioligand DOTATATE with lutetium-177 (177Lu-DOTATATE).
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.51% 22.1B
GENMAB A/S Stock Genmab A/S
-8.26% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.70% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. RACA Stock
  4. News THES ACQU
  5. Therapeutics Acquisition : POINT Biopharma To Go Public Via SPAC Combination